Form 4: Haemonetics EVP, Chief Financial Officer James D'Arecca Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
James D'Arecca, EVP and CFO of Haemonetics, reports the acquisition of common stock and stock options.
Summary
- On May 17, 2024, James D'Arecca, the EVP and Chief Financial Officer of Haemonetics Corp, reported acquiring 4,439 shares of common stock.
- These shares were awarded as restricted stock units (RSUs) under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
- The RSUs vest in three equal annual installments starting on the first anniversary of the grant date.
- Each RSU represents a contingent right to receive one share of Haemonetics common stock when vested.
- Following the transaction, D'Arecca beneficially owns 17,346 shares of common stock, which includes unvested RSUs previously reported.
- D'Arecca also acquired 9,756 non-qualified stock options with an exercise price of $95.73.
- These options vest in annual increments of 25% beginning on the first anniversary of the grant date and expire on 05/17/2031.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally a good sign, but it's a routine transaction.
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Insider transactions are routinely monitored to gauge executive sentiment and potential future performance of the company. Form 4 filings are a standard part of regulatory compliance for corporate insiders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are common in publicly traded companies like Haemonetics to align management's interests with those of shareholders.
- Vesting schedules for RSUs and stock options typically range from three to five years, with annual or quarterly vesting increments.
- The specific terms of these grants, such as the exercise price and vesting schedule, are often benchmarked against industry peers to ensure competitiveness and retention.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 05/17/2024 | Date of grant for stock options with vesting starting one year later. |
| 05/21/2024 | Date of signature on the Form 4 filing. |
| 05/17/2031 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.